Antibody and T-Cell Responses 6 Months after Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant
| العنوان: | Antibody and T-Cell Responses 6 Months after Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant |
|---|---|
| المؤلفون: | Sanders, J.F., Messchendorp, A.L., Vries, R.D. de, Baan, C.C., Baarle, D. van, Binnendijk, R. van, Diavatopoulos, D.A., Geers, D., Schmitz, K.S., GeurtsvanKessel, C.H., Hartog, G. den, Kho, M.M., Koopmans, M.P., Molen, R.G. van der, Remmerswaal, E.B.M., Rots, N., Gansevoort, R.T., Bemelman, F.J., Hilbrands, L.B., Reinders, M.E. |
| المساهمون: | Virology, Internal Medicine, Experimental Immunology, AII - Inflammatory diseases, AII - Infectious diseases, Nephrology |
| المصدر: | Clinical Infectious Diseases, 76, 3, pp. e188-e199 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3):ciac557, E188-E199. Oxford University Press Clinical infectious diseases, 76(3), E188-E199. Oxford University Press Clinical Infectious Diseases, 76, e188-e199 |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Microbiology (medical), Infectious Diseases, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], COVID-19, dialysis, kidney transplantation, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], chronic kidney disease, mRNA-1273 vaccine |
| الوصف: | Background The immune response to COVID-19 vaccination is inferior in kidney transplant recipients (KTRs) and to a lesser extent in patients on dialysis or with chronic kidney disease (CKD). We assessed the immune response 6 months after mRNA-1273 vaccination in kidney patients and compared this to controls. Methods A total of 152 participants with CKD stages G4/5 (eGFR Results At 6 months after vaccination, S1-specific antibodies were detected in 100% of controls, 98.7% of CKD G4/5 patients, 95.1% of dialysis patients, and 56.6% of KTRs. These figures were comparable to the response rates at 28 days, but antibody levels waned significantly. Neutralization of the ancestral and Delta variants was detected in most participants, whereas neutralization of Omicron was mostly absent. S-specific T-cell responses were detected at 6 months in 75.0% of controls, 69.4% of CKD G4/5 patients, 52.6% of dialysis patients, and 12.9% of KTRs. T-cell responses at 6 months were significantly lower than responses at 28 days. Conclusions Although seropositivity rates at 6 months were comparable to rates at 28 days after vaccination, significantly decreased antibody levels and T-cell responses were observed. The combination of low antibody levels, reduced T-cell responses, and absent neutralization of the newly emerging variants indicates the need for additional boosts or alternative vaccination strategies in KTRs. Clinical Trials Registration NCT04741386. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1058-4838 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd1470f01b43a20342755f789c0ec9f9 https://doi.org/10.1093/cid/ciac557 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....fd1470f01b43a20342755f789c0ec9f9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10584838 |
|---|